| 1 |
32740409 | Effect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients. | 2021 Jan |
2 |
| 2 |
33855212 | Investigating the beneficial effect of aliskiren in attenuating neuropathic pain in diabetic Sprague-Dawley rats. | 2021 Apr |
1 |
| 3 |
34514971 | Interaction of the renin inhibitor aliskiren with the SARS-CoV-2 main protease: a molecular docking study. | 2021 Sep 13 |
2 |
| 4 |
34782039 | The effects of the renin inhibitor aliskiren on neuronal toxic damage. | 2021 Nov 1 |
2 |
| 5 |
31175534 | Action Potential Triangulation Explains Acute Proarrhythmic Effect of Aliskiren in a Whole-Heart Model of Atrial Fibrillation. | 2020 Feb |
1 |
| 6 |
31605544 | The use of aliskiren as an antifibrotic drug in experimental models: A systematic review. | 2020 Feb |
1 |
| 7 |
32037898 | Add-on aliskiren treatment can decrease blood pressure but requires attention to risks of renal impairment and hyperkalemia Chikushi Anti-Hypertension Trial-Rasilez® (CHAT-Ras). | 2020 Aug 17 |
2 |
| 8 |
32083617 | Aliskiren and the dual complement inhibition concept. | 2020 Feb |
1 |
| 9 |
32200675 | Megalin: A Novel Endocytic Receptor for Prorenin and Renin. | 2020 May |
2 |
| 10 |
32202179 | Inhibition of tanshinone IIA on renin activity protected against osteoporosis in diabetic mice. | 2020 Dec |
1 |
| 11 |
32340096 | [Preliminary clinical analysis of direct renin inhibitor aliskiren in the treatment of severe coronavirus disease 2019 patients with hypertension]. | 2020 Aug 1 |
2 |
| 12 |
32914119 | Physicochemical characterisation, molecular docking, and drug-likeness evaluation of hypotensive peptides encrypted in flaxseed proteome. | 2020 Nov |
1 |
| 13 |
32922141 | Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway. | 2020 Sep |
1 |
| 14 |
29470612 | Efficacy of aliskiren supplementation for heart failure : A meta-analysis of randomized controlled trials. | 2019 Aug |
2 |
| 15 |
30631130 | The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis. | 2019 Nov |
1 |
| 16 |
31404946 | Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival. | 2019 Aug 9 |
1 |
| 17 |
28449154 | Dual RAAS Blockade with Aliskiren in Patients with Severely Impaired Chronic Kidney Disease. | 2018 Jan |
1 |
| 18 |
28464775 | Renoprotection by Direct Renin Inhibition: A Systematic Review and Meta- Analysis. | 2018 Jan 26 |
2 |
| 19 |
29143416 | Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. | 2018 Apr |
2 |
| 20 |
29618841 | Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level. | 2018 Jun |
1 |
| 21 |
29715294 | Correction: Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin. | 2018 |
1 |
| 22 |
29884545 | Aliskiren inhibits renin-mediated complement activation. | 2018 Oct |
2 |
| 23 |
29910050 | The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial. | 2018 Jul |
1 |
| 24 |
30064425 | Combination of Chymostatin and Aliskiren attenuates ER stress induced by lipid overload in kidney tubular cells. | 2018 Jul 31 |
1 |
| 25 |
30243307 | A novel role of renin inhibitor in the complement cascade. | 2018 Oct |
1 |
| 26 |
30271601 | Aliskiren reduces the release of soluble (pro)renin receptor from human umbilical vein endothelial cells. | 2018 Sep |
2 |
| 27 |
27695972 | Aliskiren decreases oxidative stress and angiogenic markers in retinal pigment epithelium cells. | 2017 Feb |
1 |
| 28 |
28356668 | Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. | 2017 Mar-Apr |
1 |
| 29 |
28379619 | Blood pressure lowering efficacy of renin inhibitors for primary hypertension. | 2017 Apr 5 |
1 |
| 30 |
28455996 | Aliskiren reduces albuminuria after kidney transplantation. | 2017 |
1 |
| 31 |
28509129 | Successful long-term effects of direct renin inhibitor aliskiren in a patient with atherosclerotic renovascular hypertension. | 2017 May |
3 |
| 32 |
28598381 | Renin Inhibition with Aliskiren: A Decade of Clinical Experience. | 2017 Jun 9 |
2 |
| 33 |
28724547 | Long-term effects of a renin inhibitor versus a thiazide diuretic on arterial stiffness and left ventricular diastolic function in elderly hypertensive patients. | 2017 Oct 1 |
1 |
| 34 |
28765966 | Aliskiren has chondroprotective efficacy in a rat model of osteoarthritis through suppression of the local renin-angiotensin system. | 2017 Oct |
3 |
| 35 |
28844155 | Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients. | 2017 Sep |
1 |
| 36 |
29046730 | Aliskiren effect on non-alcoholic steatohepatitis in metabolic syndrome. | 2017 |
1 |
| 37 |
26438325 | Direct inhibition of plasmatic renin activity with aliskiren: a promising but under-investigated therapeutic option for non-diabetic glomerulonephritis. | 2016 Feb |
2 |
| 38 |
26780837 | Novel renin inhibitors containing derivatives of N-alkylleucyl-β-hydroxy-γ-amino acids. | 2016 Feb |
1 |
| 39 |
26882043 | Maximum renal responses to renin inhibition in healthy study participants: VTP-27999 versus aliskiren. | 2016 May |
3 |
| 40 |
26935359 | Antihypertensive Efficacy of the Direct Renin Inhibitor Aliskiren as Add-on Therapy in Patients with Poorly Controlled Hypertension. | 2016 |
2 |
| 41 |
27062013 | Aliskiren directly improves endothelial progenitor cell function from Type II diabetic patients. | 2016 Jun |
1 |
| 42 |
27255757 | Utilisation and Tolerability of Aliskiren in the Primary Care Setting in England. | 2016 Dec |
2 |
| 43 |
27343695 | Aliskiren inhibits the renin-angiotensin system in retinal pigment epithelium cells. | 2016 Sep 20 |
3 |
| 44 |
27533118 | Therapeutic modulation of tissue kallikrein expression. | 2016 Dec 1 |
1 |
| 45 |
27713608 | Aliskiren Inhibits Neointimal Matrix Metalloproteinases in Experimental Atherosclerosis. | 2016 Sep |
1 |
| 46 |
31008270 | Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. | 2016 Jun |
1 |
| 47 |
23764715 | In vitro comparison of bradykinin degradation by aliskiren, a renin inhibitor, and an inhibitor of angiotensin-converting enzyme. | 2015 Jun |
1 |
| 48 |
25576239 | Nephroprotective action of renin-angiotensin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trails. | 2015 Mar |
1 |
| 49 |
25965717 | Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). | 2015 May |
2 |
| 50 |
26336535 | Oral direct renin inhibitor aliskiren reduces in vivo oxidative stress and serum matrix metalloproteinase-2 levels in patients with permanent atrial fibrillation. | 2015 Apr |
3 |